A trial of mesenchymal stem cell is planned for the end of 2010.
Preclinical work supports the use of mesenchymal stem cells to treat neurodegenerative disorders.
Clear differences were found among the control group, premanifest gene carriers, and those in early stages.
This article describes other possible diagnoses when there are clinical signs of HD but a negative gene test.
